Table of Content

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2017-2026 (USD Billion)
1.2.1. Biosimilar Monoclonal Antibody Market, by Region, 2017-2026 (USD Billion)
1.2.2. Biosimilar Monoclonal Antibody Market, by Type, 2017-2026 (USD Billion)
1.2.3. Biosimilar Monoclonal Antibody Market, by Application, 2017-2026 (USD Billion)
1.2.4. Biosimilar Monoclonal Antibody Market, by End-User, 2017-2026 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Biosimilar Monoclonal Antibody Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Biosimilar Monoclonal Antibody Market Dynamics
3.1. Biosimilar Monoclonal Antibody Market Impact Analysis (2018-2026)
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
Chapter 4. Global Biosimilar Monoclonal Antibody Market: Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2016-2026)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Biosimilar Monoclonal Antibody Market, by Type
5.1. Market Snapshot
5.2. Global Biosimilar Monoclonal Antibody Market by Type, Performance - Potential Analysis
5.3. Global Biosimilar Monoclonal Antibody Market Estimates & Forecasts by Type, 2016-2026 (USD Billion)
5.4. Biosimilar Monoclonal Antibody Market, Sub Segment Analysis
5.4.1. Synthetic Chemicals
5.4.2. Biopharmaceuticals
5.4.3. Others
Chapter 6. Global Biosimilar Monoclonal Antibody Market, by Application
6.1. Market Snapshot
6.2. Global Biosimilar Monoclonal Antibody Market by Application, Performance - Potential Analysis
6.3. Global Biosimilar Monoclonal Antibody Market Estimates & Forecasts by Application 2016-2026 (USD Billion)
6.4. Biosimilar Monoclonal Antibody Market, Sub Segment Analysis
6.4.1. Chronic & Autoimmune Diseases
6.4.2. Oncology
6.4.3. Others
Chapter 7. Global Biosimilar Monoclonal Antibody Market, Regional Analysis
7.1. Biosimilar Monoclonal Antibody Market, Regional Market Snapshot
7.2. North America Biosimilar Monoclonal Antibody Market
7.2.1. U.S. Biosimilar Monoclonal Antibody Market
7.2.1.1. Type breakdown estimates & forecasts, 2016-2026
7.2.1.2. Application Industry breakdown estimates & forecasts, 2016-2026
7.2.2. Canada Biosimilar Monoclonal Antibody Market
7.3. Europe Biosimilar Monoclonal Antibody Market Snapshot
7.3.1. U.K. Biosimilar Monoclonal Antibody Market
7.3.2. Germany Biosimilar Monoclonal Antibody Market
7.3.3. Rest of Europe Biosimilar Monoclonal Antibody Market
7.4. Asia-Pacific Biosimilar Monoclonal Antibody Market Snapshot
7.4.1. China Biosimilar Monoclonal Antibody Market
7.4.2. India Biosimilar Monoclonal Antibody Market
7.4.3. Japan Biosimilar Monoclonal Antibody Market
7.4.4. Rest of Asia Pacific Biosimilar Monoclonal Antibody Market
7.5. Latin America Biosimilar Monoclonal Antibody Market Snapshot
7.5.1. Brazil Biosimilar Monoclonal Antibody Market
7.5.2. Mexico Biosimilar Monoclonal Antibody Market
7.6. Rest of The World Biosimilar Monoclonal Antibody Market

Chapter 8. Competitive Intelligence
8.1. Top Market Strategies
8.2. Company Profiles
8.2.1. Allergan plc
8.2.1.1. Key Information
8.2.1.2. Overview
8.2.1.3. Financial (Subject to Data Availability)
8.2.1.4. Product Summary
8.2.1.5. Recent Developments
8.2.2. BIOCAD BioXpress
8.2.3. Therapeutics SA,
8.2.4. Biocon Limited
8.2.5. Boehringer Ingelheim GmbH
8.2.6. Celltrion Inc
8.2.7. Coherus BioSciences Inc
8.2.8. Dr. Reddys Laboratories Ltd
8.2.9. Genor BioPharma Co Ltd
8.2.10. Intas Pharmaceuticals Limited
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption



List of Figures


FIG 1. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, RESEARCH METHODOLOGY
FIG 2. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, MARKET ESTIMATION TECHNIQUES
FIG 3. GLOBAL MARKET SIZE ESTIMATES & FORECAST METHODS
FIG 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, KEY TRENDS 2018
FIG 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, GROWTH PROSPECTS 2019-2026
FIG 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, PORTERS 5 FORCE MODEL
FIG 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, PEST ANALYSIS
FIG 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, VALUE CHAIN ANALYSIS
FIG 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 10. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, REGIONAL SNAPSHOT 2016 & 2026
FIG 16. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODY MARKET 2016 & 2026 (USD BILLION)
FIG 17. EUROPE BIOSIMILAR MONOCLONAL ANTIBODY MARKET 2016 & 2026 (USD BILLION)
FIG 18. ASIA PACIFIC BIOSIMILAR MONOCLONAL ANTIBODY MARKET 2016 & 2026 (USD BILLION)
FIG 19. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODY MARKET 2016 & 2026 (USD BILLION)
FIG 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, COMPANY MARKET SHARE ANALYSIS (2018)


List of Tables


TABLE 1. LIST OF SECONDARY SOURCES, USED IN THE STUDY OF GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET
TABLE 2. LIST OF PRIMARY SOURCES, USED IN THE STUDY OF GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET
TABLE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, REPORT SCOPE
TABLE 4. YEARS CONSIDERED FOR THE STUDY
TABLE 5. EXCHANGE RATES CONSIDERED
TABLE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY REGION 2016-2026 (USD BILLION)
TABLE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY TYPE 2016-2026 (USD BILLION)
TABLE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY APPLICATION 2016-2026 (USD BILLION)
TABLE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY END-USER 2016-2026 (USD BILLION)
TABLE 10. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 17. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 18. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 19. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 21. U.S. BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 22. U.S. BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 23. U.S. BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 24. CANADA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 25. CANADA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 26. CANADA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 27. CANADA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 28. UK BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 29. UK BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 30. UK BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 31. UK BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 32. GERMANY BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 33. GERMANY BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 34. GERMANY BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 35. GERMANY BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 36. ROE BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 37. ROE BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 38. ROE BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 39. ROE BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 40. CHINA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 41. CHINA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 42. CHINA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 43. CHINA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 44. INDIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 45. INDIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 46. INDIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 47. INDIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 48. JAPAN BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 49. JAPAN BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 50. JAPAN BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 51. JAPAN BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 52. ROAPAC BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 53. ROAPAC BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 54. ROAPAC BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 55. ROAPAC BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 56. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 57. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 58. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 59. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 60. MEXICO BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 61. MEXICO BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 62. MEXICO BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 63. MEXICO BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 64. ROLA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 65. ROLA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 66. ROLA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 67. ROLA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 68. ROW BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 69. ROW BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 70. ROW BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 71. ROW BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)